-
1.发明申请CRYSTALLINE MODIFICATIONS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)GUANIDINE HYDROCHLORIDE AND N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)GUANIDINE SALTS 审中-公开N-（4,5-BISMETHANESULFONYL-2-METHYLBENZOYL）胍盐酸盐和N-（4,5-BISMETHANESULFONYL-2-METHYLBENZOYL）胍盐的结晶改性
公开(公告)号：WO2017137147A1
公开(公告)日：2017-08-17
申请号：PCT/EP2017/000102
申请日：2017-01-27
Applicant: MERCK PATENT GMBH
Inventor： BECKER, Axel , GALLON, Gilmary , SAAL, Christoph , KUEHN, Clemens
IPC: C07C315/06 , C07C317/44 , A61K31/155
CPC classification number: C07C317/44 , A61K31/155 , C07B2200/13
Abstract: The present invention relates to novel crystalline modifications of N-(4,5- bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride, novel N-(4,5- bismethanesulfonyl-2-methylbenzoyl)guanidine salts and their crystalline modifications and processes of manufacturing and pharmaceutical formulations thereof.
Abstract translation: 本发明涉及N-（4,5-双甲磺酰基-2-甲基苯甲酰基）盐酸胍，新颖的N-（4,5-双甲磺酰基-2-甲基苯甲酰基）胍盐和 它们的结晶变体和制造过程及其药物制剂。
-
公开(公告)号：WO2017049470A1
公开(公告)日：2017-03-30
申请号：PCT/CN2015/090326
申请日：2015-09-23
Applicant: XW LABORATORIES INC.
Inventor： XIANG, Jia-Ning , XU, Xuesong , ZHANG, Xuan
IPC: C07C53/124 , C07C229/00 , A61K31/19 , A61P25/00
CPC classification number: C07C229/36 , A61K45/06 , C07B59/001 , C07B2200/05 , C07B2200/07 , C07C69/24 , C07C69/612 , C07C69/618 , C07C69/67 , C07C69/74 , C07C69/75 , C07C69/76 , C07C69/78 , C07C69/80 , C07C69/82 , C07C69/92 , C07C69/96 , C07C229/08 , C07C255/57 , C07C271/22 , C07C317/44 , C07C2601/08 , C07C2601/14 , C07D207/16 , C07D213/79 , C07D213/80 , C07D277/56 , C07D307/68 , C07D333/38
Abstract: The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
Abstract translation: 本申请公开了γ-羟基丁酸的前药以及其组合物和用途。
-
公开(公告)号：WO2016193470A1
公开(公告)日：2016-12-08
申请号：PCT/EP2016/062712
申请日：2016-06-03
Applicant: LEAD PHARMA CEL MODELS IP B.V. , SANOFI
Inventor： CALS, Joseph Maria Gerardus Barbara , DE KIMPE, Vera , NABUURS, Sander Bernardus , CADICAMO, Cosimo Damiano , LEMMERS, Jaap Gerardus Henricus
IPC: C07D213/75 , C07D231/12 , C07D333/36 , C07D233/61 , C07C311/20 , C07C317/32 , C07D409/04 , C07D249/08 , C07D263/32 , C07D271/06 , C07D277/46 , A61K31/10 , A61K31/18 , A61P29/00 , A61P37/00
CPC classification number: C07C317/32 , A61K31/167 , A61K31/381 , A61K31/415 , A61K31/4164 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/4402 , A61K31/4436 , A61K31/4439 , C07C311/20 , C07C317/44 , C07C2601/02 , C07D213/72 , C07D213/75 , C07D231/12 , C07D233/61 , C07D249/08 , C07D263/32 , C07D271/06 , C07D277/46 , C07D277/54 , C07D333/36 , C07D409/04 , C07D417/12
Abstract: The present invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐。 该化合物可用作RORY的抑制剂，可用于治疗RORy介导的疾病。
-
公开(公告)号：WO2016193459A1
公开(公告)日：2016-12-08
申请号：PCT/EP2016/062696
申请日：2016-06-03
Applicant: LEAD PHARMA CEL MODELS IP B.V. , SANOFI
IPC: C07D213/75 , C07D215/08 , C07D231/40 , C07C317/32 , C07D261/08 , C07D261/14 , C07D207/325 , C07D277/46 , C07D285/135 , C07D211/16 , C07D307/52 , A61K31/10 , A61P37/00 , A61P29/00
CPC classification number: C07C317/44 , A61K31/167 , A61K31/341 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/433 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/451 , A61K31/47 , C07C2601/02 , C07C2601/04 , C07D207/06 , C07D207/325 , C07D211/16 , C07D213/71 , C07D213/75 , C07D215/08 , C07D231/40 , C07D261/08 , C07D261/14 , C07D277/46 , C07D285/135 , C07D307/14 , C07D307/22 , C07D307/52
Abstract: The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases such as autoimmune and inflammatory diseases.
Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐。 该化合物可用作RORY的抑制剂，可用于治疗RORy介导的疾病，例如自身免疫性和炎性疾病。
-
公开(公告)号：WO2016001073A1
公开(公告)日：2016-01-07
申请号：PCT/EP2015/064484
申请日：2015-06-26
Applicant: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
Inventor： AHRENS, Hartmut , TIEBES, Jörg , WALDRAFF, Christian , DIETRICH, Hansjörg , GATZWEILER, Elmar , ROSINGER, Christopher Hugh , SCHMUTZLER, Dirk
IPC: C07D249/14 , C07D257/06 , C07D271/04 , C07D271/10 , C07C317/44 , C07C321/28 , C07C323/56 , A01N43/82 , A01N43/653 , A01N43/713
CPC classification number: C07C317/44 , A01N43/653 , A01N43/713 , A01N43/82 , C07C323/56 , C07D249/14 , C07D257/06 , C07D271/04 , C07D271/08 , C07D271/10 , C07D271/113
Abstract: Es werden Benzoesäureamide der allgemeinen Formel (I) als Herbizide beschrieben. In dieser Formel (I) stehen X, Z und R für Reste wie Alkyl und Cycloalkyl. Q bedeutet einen 5-gliedrigen Heterocyclus.
Abstract translation: 还有被描述为通式（I）的除草剂苯甲酸酰胺。 在该式（I）中X，Z和R如烷基和环烷基，例如。 Q表示的5元杂环。
-
Patent Agency Ranking
公开(公告)号：WO2015073864A8
公开(公告)日：2016-01-07
申请号：PCT/US2014065765
申请日：2014-11-14
Applicant: WISTAR INST
Inventor： MESSICK TROY E , SMITH GARRY R , REITZ ALLEN B , LIEBERMAN PAUL M
IPC: C07C229/56
CPC classification number: C07D207/327 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C211/27 , C07C217/84 , C07C229/56 , C07C229/64 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C255/54 , C07C255/55 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07C317/44 , C07C2601/02 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/70 , C07D213/55 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/06 , C07D239/26 , C07D249/06 , C07D277/30 , C07D295/155 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10 , C07D403/10 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04
Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Abstract translation: 本发明的药物组合物包含可用于治疗由EBNA1活性引起的疾病如EB病毒，感染性单核细胞增多症，慢性疲劳综合征，多发性硬化症，系统性红斑狼疮和类风湿性关节炎的EBNA1抑制剂。 本发明的药物组合物还包含可用于治疗潜伏性爱泼斯坦 - 巴尔病毒（EBV）感染引起的疾病的EBNA1抑制剂。 本发明的药物组合物还包含可用于治疗由溶血性爱泼斯坦 - 巴尔病毒（EBV）感染引起的疾病的EBNA1抑制剂。
-
公开(公告)号：WO2015191430A1
公开(公告)日：2015-12-17
申请号：PCT/US2015/034648
申请日：2015-06-08
Applicant: DOW AGROSCIENCES LLC
Inventor： LEPLAE, Paul Renee , HUNTER, James E. , WATSON, Gerald B. , LO, William C. , HERBERT, John
IPC: C07C233/66 , C07C251/40
CPC classification number: C07C225/16 , A01N33/08 , A01N37/18 , A01N37/20 , A01N37/26 , A01N37/28 , A01N37/34 , A01N37/36 , A01N37/44 , A01N41/10 , A01N53/00 , C07B2200/07 , C07C233/78 , C07C233/83 , C07C243/38 , C07C255/19 , C07C255/46 , C07C317/28 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/02
Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula.
Abstract translation: 本公开涉及具有杀虫效果的分子领域，其用于杀虫剂，节肢动物和/或软体动物中的害虫，产生此类分子的方法和用于此类方法的中间体，含有这些分子的组合物，以及使用此类分子对这种害虫 。 这些分子可以用作例如杀线虫剂，杀螨剂，杀虫剂，杀螨剂和/或杀软体动物剂。 该文献公开了具有下式的分子。
-
公开(公告)号：WO2015073864A1
公开(公告)日：2015-05-21
申请号：PCT/US2014/065765
申请日：2014-11-14
Applicant: THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventor： MESSICK, Troy, E. , SMITH, Garry, R. , REITZ, Allen, B. , LIEBERMAN, Paul, M.
IPC: C07C229/56
CPC classification number: C07D207/327 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C211/27 , C07C217/84 , C07C229/56 , C07C229/64 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C255/54 , C07C255/55 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07C317/44 , C07C2601/02 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/70 , C07D213/55 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/06 , C07D239/26 , C07D249/06 , C07D277/30 , C07D295/155 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10 , C07D403/10 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04
Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Abstract translation: 本发明的药物组合物包含可用于治疗由EBNA1活性引起的疾病如EB病毒，感染性单核细胞增多症，慢性疲劳综合征，多发性硬化症，系统性红斑狼疮和类风湿性关节炎的EBNA1抑制剂。 本发明的药物组合物还包含可用于治疗潜伏性爱泼斯坦 - 巴尔病毒（EBV）感染引起的疾病的EBNA1抑制剂。 本发明的药物组合物还包含可用于治疗由溶血性爱泼斯坦 - 巴尔病毒（EBV）感染引起的疾病的EBNA1抑制剂。
-
公开(公告)号：WO2015024010A3
公开(公告)日：2015-04-16
申请号：PCT/US2014051459
申请日：2014-08-18
Applicant: UNIV DUKE
Inventor： ZHOU PEI , TOONE ERIC J , NICHOLAS ROBERT A
CPC classification number: C07C259/06 , A61K31/5375 , C07C317/44 , C07D213/64 , C07D231/12 , C07D295/135 , C07D295/155
Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1,X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
Abstract translation: 公开了式（I）和（II）的化合物及其药学上可接受的盐，其中R，R 1，R 2，R 3，R 21，R 22，R 23，R 34，R 37，R 33，R 39，D，Q， Y，X，X1，X3和X4在本文中定义。 这些化合物可用于治疗革兰氏阴性菌感染。
-
公开(公告)号：WO2014194984A1
公开(公告)日：2014-12-11
申请号：PCT/EP2014/001354
申请日：2014-05-20
Applicant: MERCK PATENT GMBH
Inventor： PAHNKE, Joerg , JONSCHKER, Gerhard , SCHELLENBERGER, Steffen
IPC: A01N25/30
CPC classification number: C07C317/44 , A01N25/30 , A01N41/10
Abstract: Die vorliegende Erfindung betrifft die Verwendung von Fluortensiden der Formel (I) in Pestiziden.
Abstract translation: 本发明涉及使用在杀虫剂的式（I）的氟化表面活性剂的。
-
-
-
-
-
-
-
-
-
Search Results
717
records
(took 0.033 seconds)
